Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$27.25 USD

27.25
322,456

+0.98 (3.73%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $27.28 +0.03 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (148 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.

Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down

Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.

Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail

Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes

Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.

OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?

OMCL vs. PRVA: Which Stock Is the Better Value Option?

Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down

Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.

Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised

Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Is Omnicell (OMCL) Up 9.7% Since Last Earnings Report?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.

Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.

Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up

Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down

Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.

Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 457.14% and 4.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply

Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.

NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care

NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.

Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 36.80% and 72.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Down 2.8% Since Last Earnings Report: Can It Rebound?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.